ConductScience.org, home

Paper40940908

Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?

Ceniceros L and 7 others. Cancers (Basel), 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next? Papers, record 40940908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40940908

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?
PubMed
Journal
Cancers (Basel)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-09-25
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ceniceros LLucíahttps://orcid.org/0000-0003-1459-5159
2Torre MManuel de Lahttps://orcid.org/0000-0002-1972-3933
3Landa Magdalena AAna
4Sangro PPalomahttps://orcid.org/0000-0001-9753-9667
5Argemí JJosepmariahttps://orcid.org/0000-0003-1696-7753
6D'Avola DDelia
7Sangro BBrunohttps://orcid.org/0000-0002-4177-6417
8Ponz-Sarvisé MMarianohttps://orcid.org/0000-0002-3240-729X

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References59

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114534886Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.Cancer2003https://conductscience.org/library/papers/14534886PubMed
219809471The functional plasticity of T cell subsets.Nat Rev Immunol2009https://conductscience.org/library/papers/19809471PubMed
334998048Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.Eur J Cancer2022https://conductscience.org/library/papers/34998048PubMed
432461347Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.J Immunother Cancer2020https://conductscience.org/library/papers/32461347PubMed
534907910Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.J Clin Invest2021https://conductscience.org/library/papers/34907910PubMed
628928458Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.Nat Commun2017https://conductscience.org/library/papers/28928458PubMed
735680043Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.Ann Oncol2022https://conductscience.org/library/papers/35680043PubMed
836681415Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet2023https://conductscience.org/library/papers/36681415PubMed
940381735Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.J Hepatol2025https://conductscience.org/library/papers/40381735PubMed
1031875970Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.Hepatology2020https://conductscience.org/library/papers/31875970PubMed
1135311147Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma.Front Oncol2022https://conductscience.org/library/papers/35311147PubMed
1224136146Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer.Br J Cancer2013https://conductscience.org/library/papers/24136146PubMed
1335621637Immune Checkpoint Inhibitors in Cancer Therapy.Curr Oncol2022https://conductscience.org/library/papers/35621637PubMed
1432416072Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020https://conductscience.org/library/papers/32416072PubMed
1527095655Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nat Rev Gastroenterol Hepatol2016https://conductscience.org/library/papers/27095655PubMed
1632359091Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.Int J Cancer2020https://conductscience.org/library/papers/32359091PubMed
1729405274Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.Br J Surg2018https://conductscience.org/library/papers/29405274PubMed
1831535160Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.Cancer Immunol Immunother2019https://conductscience.org/library/papers/31535160PubMed
1938493667Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).Eur J Cancer2024https://conductscience.org/library/papers/38493667PubMed
2028975832Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.Cancer Control2017https://conductscience.org/library/papers/28975832PubMed

See all 59 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42169927Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151.J Gastrointest Oncol2026https://conductscience.org/library/papers/42169927PubMed
41639545Surgical management of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a narrative review of principles, technical nuances, and emerging strategies.J Liver Cancer2026https://conductscience.org/library/papers/41639545PubMed
41394868Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment.Front Immunol2025https://conductscience.org/library/papers/41394868PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40940908

GET https://conductscience.org/api/papers/v1/40940908/references?page=2